Dear Sir, Islet cell antibodies (ICAb) become undemonstrable by immunofluorescence in most cases within a few years after the diagnosis of Type 1 (insulin-dependent) diabetes mellitus. This is explained by the loss of an antigenic reservoir as the islet beta cells are completely destroyed [1] . Autoantibodies to glutamic acid decarboxylase (GAD), previously known as the 64 kDa autoantigen [2, 3] , earlier appeared to fade in a similar way. Thus, Kaufman et al. [4] reported that levels and frequency of anti-GAD decreased markedly during the first years after detection, and when these did persist, an explanation invoked was diabetic neuropathy which could allow GAD to leak from the demaged peripheral nerves and sustain or reactivate the antibody response. Our experience is inconsistent with this idea.
We find that the decrease in frequency of positivity for anti-GAD in Type 1 diabetic patients is not nearly as great as for ICA b. Among the sera studied during 1991-1992, anti-GAD was positive for 147 of 207 (71%) cases of Type I diabetes with a duration 0-5 years, 50 of 85 (59 % ) cases with a duration 6-10 years, and 48 of 89 (54 %) cases with duration over 10 years.
Furthermore, we studied 32 diabetic patients with severe polyneuropathy which had been verified by nerve conduction studies. These were 18 with Type 1 diabetes, ten female and eight male, with a mean age of 52 + 11 years, a mean age at onset of diabetes of 30 _+ 13 years, and a disease duration of 22 + 7 years; and 14 with Type 2 diabetes, four female and ten male, with a mean age of 61 + 8 years, a mean age at onset of 48 + 9 years, and a disease duration of 13 + 8 years. Anti-GAD was tested for by a radioimmunoprecipitation assay [5] . Of the Type 1 diabetic patients, 10 of 18 were positive for anti-GAD (56 %), a frequency similar to that found for all Type i diabetic patients of more than 10 years duration irrespective of the presence or not of clinically evident neuropathy. None of the 14 patients with Type 2 diabetes and clinically evident neuropathy were positive. In addition, we tested sera from 42 patients with leprosy, 23 female and 19 male, which, in the tuberculoid andintermediate forms, is often accompanied by peripheral neuropathy and antibodies to constituents of both nerves and skin [6] . In this group, 28 had polar lepromatous leprosy, 10 had intermediate lepromatous-tuberculoid leprosy, and 4 had polar tuberculous leprosy.
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Only one serum, from a patient with polar lepromatous leprosy, was positive for anti-GAD, and this weakly so (48 units; upper normal limit, defined as mean + 3 SD of blood donor sera, is 20 units).
In conclusion, we can infer that in Type i diabetes levels of anti-GAD persist for long periods unlike ICAb, and this persistence is not explained by diabetic neuropathy. Also, the existence of neuropathy of itself, and in the absence of the genetic-environmental background particular to Type 1 diabetes, is not associated with an anti-GAD response.
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